Autolus Therapeutics plc (AUTL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 40M 80M 120M Q1 '19: 3M Q2 '19: 2.9M Q3 '19: 2.9M Q4 '19: 2.9M Q1 '20: 1.3M Q2 '20: 1.2M Q4 '24: 10.1M Q1 '25: 9M Q2 '25: 29.9M Q3 '25: 51.1M Q4 '25: 75.4M Q1 '26: 92.6M Q2 '26: 117.4M Q1 '19 Q3 '19 Q1 '20 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit TTM

-45M -30M -15M 0 15M 30M 45M Q4 '24: -1.3M Q1 '25: -20.3M Q2 '25: -23.8M Q3 '25: -31.3M Q4 '25: -21M Q1 '26: -10.4M Q2 '26: 18.4M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '19: -128M Q4 '19: -146.1M Q1 '20: -154.5M Q2 '20: -156.8M Q3 '20: -163.9M Q4 '20: -168.1M Q1 '21: -169.5M Q4 '22: -130.4M Q1 '23: -133.4M Q2 '23: -138.7M Q3 '23: -138.1M Q4 '23: -179.7M Q1 '24: -179.3M Q2 '24: -193.9M Q3 '24: -218.8M Q4 '24: -241.4M Q1 '25: -267.9M Q2 '25: -270.2M Q3 '25: -273.9M Q4 '25: -270.5M Q1 '26: -264.8M Q2 '26: -247.4M Q3 '19 Q2 '20 Q1 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-300M -200M -100M 0 100M 200M 300M Q3 '18: -44.8M Q4 '18: -57.9M Q1 '19: -68.3M Q2 '19: -89.2M Q3 '19: -103.6M Q4 '19: -123.8M Q1 '20: -126.5M Q2 '20: -130.1M Q3 '20: -140.2M Q4 '20: -142.1M Q1 '21: -145.5M Q4 '22: -148.8M Q1 '23: -151.6M Q2 '23: -155.1M Q3 '23: -158.2M Q4 '23: -208.4M Q1 '24: -221.3M Q2 '24: -234M Q3 '24: -270.2M Q4 '24: -220.7M Q1 '25: -238.1M Q2 '25: -227.8M Q3 '25: -224.8M Q4 '25: -287.5M Q1 '26: -289M Q2 '26: -280.2M Q4 '18 Q4 '19 Q4 '20 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue TTM

0 40M 80M 120M Q4 '24: 11.4M Q1 '25: 29.3M Q2 '25: 53.8M Q3 '25: 82.4M Q4 '25: 96.4M Q1 '26: 103M Q2 '26: 99M Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

Operating Cash Flow TTM

-300M -200M -100M 0 100M 200M 300M Q2 '19: -80.7M Q3 '19: -88M Q4 '19: -101.5M Q1 '20: -99M Q2 '20: -108.7M Q3 '20: -123.3M Q4 '20: -117.8M Q1 '21: -131.1M Q3 '23: -135.3M Q4 '23: -145.6M Q1 '24: -143.7M Q2 '24: -156.6M Q3 '24: -193.2M Q4 '24: -206.3M Q1 '25: -241.3M Q2 '25: -263M Q3 '25: -254.2M Q4 '25: -283.6M Q1 '26: -273.3M Q2 '26: -225.6M Q3 '19 Q2 '20 Q1 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q2 '19: -105M Q3 '19: -109.2M Q4 '19: -119.8M Q1 '20: -112.6M Q2 '20: -119.2M Q3 '20: -134.1M Q4 '20: -132.4M Q1 '21: -145M Q3 '23: -145.5M Q4 '23: -156.6M Q1 '24: -151.6M Q2 '24: -161M Q3 '24: -205.6M Q4 '24: -228.3M Q1 '25: -271.1M Q2 '25: -299.2M Q3 '25: -285.2M Q4 '25: -302.6M Q1 '26: -286.8M Q2 '26: -232.7M Q3 '19 Q2 '20 Q1 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 100M 200M 300M Q1 '22: 90.9M Q2 '22: 90.9M Q3 '22: 91.2M Q1 '23: 173.8M Q2 '23: 173.9M Q3 '23: 174M Q1 '24: 222.2M Q2 '24: 266M Q3 '24: 266.1M Q1 '25: 266.1M Q2 '25: 266.1M Q3 '25: 266.1M Q1 '26: 266.1M Q2 '26: 266.2M Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-3.00 -2.00 -1.00 0.00 1.00 2.00 3.00 Q1 '19: -1.80 Q2 '19: -2.19 Q3 '19: -2.47 Q4 '19: -2.88 Q1 '20: -2.79 Q2 '20: -2.76 Q3 '20: -2.87 Q4 '20: -2.77 Q1 '21: -2.70 Q4 '22: -1.57 Q1 '23: -1.39 Q2 '23: -1.19 Q3 '23: -0.98 Q4 '23: -1.20 Q1 '24: -1.21 Q2 '24: -1.17 Q3 '24: -1.22 Q4 '24: -0.86 Q1 '25: -0.88 Q2 '25: -0.84 Q3 '25: -0.83 Q4 '25: -1.08 Q1 '26: -1.09 Q2 '26: -1.06 Q3 '19 Q2 '20 Q1 '21 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.